- Looking at objective indicators, one has to conclude that in key cancers, patient survival rates are increasing. Unfortunately, prevention remains a sore point," the expert admitted.
Perhaps not a sore point, but certainly a challenge, is the personalization of therapy. As Prof. Rutkowski stressed, at the moment the guidelines provide for the implementation of molecular diagnostics and therapy based on its results - but in some cancers the goal has not yet been achieved. One of the problems is the need to accredit centers that will perform the best quality molecular tests, it is also necessary, the specialist hinted, to simplify bureaucratic issues (at the moment, for example, the patient must give consent for each test separately), and finally - last but not least - to ensure full reimbursement of available tests.
The groundbreaking role of the tests for patients and the system was pointed out by Dr. Michal Jarzab, Center for Diagnosis and Treatment of Breast Diseases at the Maria Sklodowska-Curie National Cancer Institute. Maria Sklodowska-Curie - National Research Institute in Gliw...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
